In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Hold rating on Travere Therapeutics (TVTX – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $6.29.
Thompson CFA covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Aclaris Therapeutics, and Spyre Therapeutics. According to TipRanks, Thompson CFA has an average return of 6.2% and a 51.35% success rate on recommended stocks.
In addition to Stifel Nicolaus, Travere Therapeutics also received a Hold from Wells Fargo’s Mohit Bansal in a report issued yesterday. However, today, Citi assigned a Buy rating to Travere Therapeutics (NASDAQ: TVTX).
See today’s best-performing stocks on TipRanks >>
Based on Travere Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $37.1 million and a net profit of $150.74 million. In comparison, last year the company earned a revenue of $28.08 million and had a GAAP net loss of $69.66 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Travere Therapeutics (TVTX) Company Description:
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Read More on TVTX:
- Travere Therapeutics price target lowered to $19 from $23 at JPMorgan
- Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
- Travere Therapeutics initiated with a Neutral at Citi
- Travere Therapeutics Reports Third Quarter 2023 Financial Results
- TVTX Upcoming Earnings Report: What to Expect?
